NAMS

Newamsterdam Pharma Stock Analysis

AI Rating

Fair
  • Quality3/10
  • Growth↑ 5/10
  • Value↓ 0/10
Newamsterdam Pharma sales and earnings growth
NAMS Growth
Neutral
  • Revenue Y/Y↓ -54.28%
  • EPS Y/Y↓ 4.79%
  • FCF Y/Y↓ -1.03%
Newamsterdam Pharma gross and profit margin trends
NAMS Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -942.80%
  • ROIC 5Y↓ 0.00%
Newamsterdam Pharma net debt vs free cash flow
NAMS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Newamsterdam Pharma stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks